Department of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Gastrointest Endosc. 2021 Mar;93(3):557-564.e1. doi: 10.1016/j.gie.2020.06.067. Epub 2020 Jul 2.
Endoscopic submucosal dissection (ESD) has become an important and minimally invasive treatment for early gastric cancer (EGC) with a negligible risk of metastasis not only for differentiated-type (D-type) cancer but also for undifferentiated-type (UD-type) cancer. We aimed to investigate the incidence and characteristics of metachronous cancer after ESD for UD-type cancer, which has not yet been elucidated.
In total, 175 patients who underwent ESD for UD-type EGC were enrolled. For comparison, 350 patients who underwent ESD for D-type EGC during the same period were randomly selected. These patients underwent a follow-up EGD annually. The median observation period was 6.0 years and 5.4 years, respectively.
The annual incidence of metachronous cancer after ESD for UD-type and D-type cancer was .9% and 5.3%, respectively. Among the patients who underwent ESD for UD-type cancer, 30.9% of patients were uninfected with Helicobacter pylori, whereas all patients who underwent ESD for D-type cancer were infected with H pylori. All patients who developed metachronous cancer were infected with H pylori. UD-type metachronous cancer developed more frequently in patients after ESD for UD-type cancer than after ESD for D-type cancer, and the curative resection rate of ESD was significantly lower in these cases.
Metachronous cancers developed only in H pylori-infected patients in this cohort. Although metachronous cancer incidence was significantly less frequent in patients after ESD for UD-type cancer, the curative resection rate of ESD was significantly lower. Routine surveillance should be conducted more carefully after ESD for UD-type cancer, especially in H pylori-infected patients.
内镜黏膜下剥离术(ESD)已成为治疗早期胃癌(EGC)的重要微创手段,不仅对分化型(D 型)癌,而且对未分化型(UD 型)癌的转移风险也可忽略不计。我们旨在探讨尚未阐明的 ESD 治疗 UD 型胃癌后发生异时性癌症的发生率和特征。
共有 175 例接受 UD 型 EGC ESD 治疗的患者入选。为了进行比较,同期随机选择了 350 例接受 D 型 EGC ESD 治疗的患者。这些患者每年接受一次内镜随访。中位观察期分别为 6.0 年和 5.4 年。
ESD 治疗 UD 型和 D 型癌症后异时性癌症的年发生率分别为 0.9%和 5.3%。在接受 UD 型 ESD 治疗的患者中,30.9%的患者未感染幽门螺杆菌(H.pylori),而所有接受 D 型 ESD 治疗的患者均感染了 H.pylori。所有发生异时性癌症的患者均感染了 H.pylori。与接受 D 型 ESD 治疗的患者相比,接受 UD 型 ESD 治疗的患者发生 UD 型异时性癌症的频率更高,并且这些患者的 ESD 完全切除率明显更低。
在本队列中,异时性癌症仅在 H.pylori 感染的患者中发展。尽管接受 UD 型 ESD 治疗的患者异时性癌症的发生率明显较低,但 ESD 的完全切除率明显较低。在接受 UD 型 ESD 治疗后,应更仔细地进行常规监测,尤其是在 H.pylori 感染的患者中。